Amarin Provides Overview on Growing Global Attention on REDUCE-IT™ Results and Cardiovascular Risk Management Beyond Cholesterol Management
Last amarin corp plc ads earnings: 4/30 05:00 am
Check Earnings Report
US:NASDAQ Investor Relations: investor.amarincorp.com/investors
Multiple Papers and Presentations Highlight REDUCE-IT and Vascepa®Potential Mechanisms of Action of Vascepa Becoming Better Understood American Heart Association References REDUCE-IT in Scientific Advisory BEDMINSTER, N.J. and DUBLIN, Ireland, Aug. 27, 2019 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a pharmaceutical company focused on improving cardiovascular health, today provided an update on the growing interest in information on Amarin’s REDUCE-IT™ study and the potential for use of Vascepa® (icosapent ethyl) in studied patients at risk for a cardiovascular event. Cardiovascular disease (CVD) is worldwide the #1 killer of men and women.1,2 REDUCE-IT studied the effects of Vascepa on the reduction of major adverse cardiovascular events in a high-risk patient population. The study results are currently under regulatory review in the United States and Canada. Publications Increasingly Highlight REDUCE-IT and Vascepa Publications and other scientific discussions h
[Read more]
| Impact snapshot | Event time: | AMRN | ||||
|---|---|---|---|---|---|---|
|
Last Price
|
Price Change
|
Price Change %
|
Volume Shares
|
Max Up
|
Max Down
|
Volume Ratio
%
|
Performance comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last price | ||
| VWAP | ||
|
High:
|
Max up |
High:
|
|
Low:
|
Max down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event Day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance Since Event
Time and Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
SIGN UP TODAY
Opt-in for
AMRN alerts
AMRN alerts
from News Quantified
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AMRN alerts
High impacting Amarin Corp Plc ADS news events
Weekly update
A roundup of the hottest topics
AMRN
News
- Amarin to Report Second Quarter and Six Month 2021 Financial Results and Host Conference Call on August 5, 2021GlobeNewswire
- Pharmaceutical Executive® APEX Awards Announces 2021 FinalistsPR Newswire
- Amarin Co. plc (<a href="https://www.marketbeat.com/stocks/NASDAQ/AMRN/price-target/">NASDAQ: AMRN</a>) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "strong-buy" rating. They now have a $5.50 price targMarketBeat
- U.S. Supreme Court denies Amarin's bid to revive Vascepa drug patents [Financial Post (Toronto, Ontario, Canada)]Financial Post
- U.S. Supreme Court denies Amarin's bid to revive Vascepa drug patents [Financial Post (Toronto, Ontario, Canada)]Financial Post
- More
AMRN
SEC Filings
- 8/3/21 - Form 4
- 8/3/21 - Form 4
- 8/3/21 - Form 4
- AMRN's page on the SEC website
- More